For many mothers, their happy moment welcoming their baby into the world, can give way to a deep and severe depression. Postnatal depression occurs in more than 10 per cent of mothers over the first year post-delivery. 85 percent of new mothers suffer the ‘baby blues’.
Reports often focus on the risks of using antidepressants during pregnancy and new mothers taking medication, cautioning of the dangers of passing on traces of the drugs, for those who breastfeed.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
But according to the new systematic review by the Institute of Psychiatry at King’s College London, “Trials of 596 women found that Antidepressants are associated with better rates of treatment response and remission for women with postnatal depression”.
Guidelines recommend psychological interventions for mild to moderate depression, and that the risk-benefit ratio of antidepressants be considered before using them in the postnatal period, including the effect of medication on baby and mother and the likely benefit of psychological intervention.
Remission rates (i.e. no longer meeting validated criteria for depression) were also improved, with 49 per cent of participants randomised to SSRIs showing remission compared to 26 per cent in the placebo group. These findings related to a treatment period of between six to eight weeks.
Emma Molyneaux, first author from the IoPPN at King’s College London, said:
‘Our findings are important due to the limited research exploring the use of antidepressants to treat postnatal depression. We would urge that treatment decisions during the postnatal period consider the potential benefits as well as risks of medication, as well as the risks of untreated depression for both mother and baby.’
Kylee Trevillion, co-author and post-doctoral researcher at the IoPPN, said: ‘There have been relatively few trials of antidepressants for postnatal depression and few studies to date have included women with severe depression. Postnatal depression impacts not only the mother but also the rest of the family – more research is needed in this area to improve outcomes for mothers and their families.’
NIHR-funded Professor Louise Howard, senior author from the IoPPN, said: ‘Some antidepressants are safer than others for mothers who are breastfeeding, so mothers seeking advice for depressive symptoms should ensure that their doctor knows if they are breastfeeding.’
The research, published in the Journal of the American Medical Association (JAMA)
